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Abstract 
Purpose: To increase the refolding yield of Recombinant Human Interferon α-2b in order to achieve a 
highly potent product. 
Methods: Interferon α-2b inclusion body was dissolved in tris-HCl buffer containing 6 M guanidine-HCl 
and CuSO4. Different refolding buffers were employed for refolding the target protein. The refolded 
proteins were then purified by affinity and gel filtration chromatography. The purified proteins were 
subjected to circular dichroism (CD) spectropolarimetry and assayed for biological activity in vitro.  
Results: Increment of pH to 8.5 improved refolding efficacies from 42.28 % to 71.22 %. However, the 
relative potency significantly increased up to pH 8.0 (from 19353546 to 28633902, p < 0.05) and then 
decreased to 21081305.00 at pH 8.5. The CD spectra demonstrated that by increasing pH to 8.5, the 
secondary structure of the protein was altered, probably due to increase in alpha-helix from 23.7 % at 
pH 7.0 to 28.1 %.    
Conclusion: Employing a low-cost and simple method, such as alteration of refolding buffer pH, results 
in higher refolding yield in downstream processing of rhIFN α-2b.  
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Large scale production of bio-pharmaceuticals 
has been made possible by recombinant DNA 
technology. Biomolecules produced via 
biotechnology are increasing, posing challenges 
and obstacles [1-3]. One of the recombinant 
proteins produced by such technology is 
interferon, with anti-viral, anti-proliferative, and 
immunomodulatory properties [4].  
 
Recombinant human interferon α-2b (rhIFN α-2b) 
is currently produced as insoluble aggregate 
forms through recombinant technology 
employing Escherichia coli. The aggregated 
proteins are further processed in order to obtain 
functional forms of target protein in vitro [2-5]. 
Thus such proteins are outcomes of high-level 
expression of eukaryotic proteins deposited in 
cytoplasm of E. coli referred to as inclusion 
bodies (IBs) [3,4,6-8]. Protein properties such as 
net charge, turn-forming residual fraction, 
cysteine and proline fractions, and hydrophilicity 
correlate with inclusion body formation. Other 
factors controlling the partitioning of recombinant 
proteins are temperature, pH, and nutrient 
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constituents of culture/fermentation medium 
[4,8].  
 
It has long been reported that IBs are formed 
with unfolded or misfolded polypeptides that are 
devoid of biological activity [9,10]. Hence, the 
occurrence of IBs is deemed to be problematic in 
a biotechnological context, which results in major 
economic impacts particularly when protein 
refolding from inclusion bodies becomes 
necessary [3,8,9,11]. The formation of IBs is 
usually the consequence of the rapid 
accumulation of newly synthesized polypeptides 
[4,12]. This occurs when rates of protein 
synthesis overwhelm the folding machinery or 
the cell's capacity for post-translational 
modification [13]. However, IBs cause obstacles 
in downstream processing in biotechnology 
industries. This obstacle can be solved by 
addition of solubilizing agents, initial protein 
recovery, and protein renaturation [8,14]. In this 
study we attempted to increase the refolding 
yield of rhIFN α-2b through pH alteration by 




Solubilization of inclusion body 
 
The IB in buffer (50 mM Tris-HCl and 50 mM 
NaCl, pH 7.0) was supplied by the Department of 
rhIFN α-2b production, Research and Production 
Complex, Pasteur Institute of Iran. It was thawed 
and then precipitated by centrifugation at 3000 g 
and at 4 °C for 15 min. The supernatant was 
decanted and the pellet was weighed. 
Subsequently, 25 mL of denaturing buffer (50 
mM Tris-HCl, 50 mM NaCl and 8 M guanidine 
HCl pH 7.0) containing 115 mg dithiothreitol 
(DTT, Merck, Germany) was added to each 0.3 g 
of pellet and slowly stirred for 2 h at 4 °C to 
solubilize the protein. The insoluble fraction was 
then separated by centrifugation at 5000 g, and 
at 4 °C for 15 min. The soluble protein was 
filtered through 0.2 µM filter and evaluated by 
Bradford protein assay using bovine serum 
albumin (Sigma Aldrich A4737) as standard [15]. 
Finally, the protein concentration was adjusted to 
5 mg/mL by adding denaturing buffer to minimize 
the concentration effect on refolding yield. The 
protein solution was employed in carrying out the 
refolding process at different pH conditions. 
 
Refolding of rhIFN α-2b 
 
All refolding processes were performed 
batchwise at 4 °C and the refolding efficiency 
was determined as the ratio of solubilized protein 
concentration to the total denatured protein 
[16,17] at pH 7.0, 7.5, 8.0 and 8.5. The refolding 
buffer (50 mM Tris-HCl and 50 mM NaCl) was 
prepared at various pHs (pH 7.0, 7.5, 8.0 and 
8.5). The buffer of pH 7.0 was considered as 
control for refolding. Effects of different pH 
values on refolding of rhIFN α-2b were studied. 
by addition of 22.5 mL of each refolding buffer at 
different pH containing 2.5 µL of 80 mM CuSO4 
to 2.5 mL of denatured protein (5 mg/mL) in 
separate 50 mL beakers using a peristaltic pump 
(Bio-Rad, USA) at the flow rate of 0.06 ml/min for 
6 h with gentle stirring using magnetite stirrers 
with similar size and shape (PLT Scientific, 
Thailand). Each experiment was performed in 
triplicate. The speed of stirrers was adjusted to 
150 rpm such a way there was no foam 
formation. Finally, refolding efficacy was 
calculated for each pH. 
 
Purification of refolded rhIFN α-2b 
 
The purification procedures were as similar for all 
proteins obtained at different pH values to 
minimize data variation affected by purification 
steps. The purification steps were composed of 
two sequential column chromatography including 
immobilized metal affinity chromatography 
(IMAC) and size exclusion chromatography 
(SEC). All solutions and buffers were HPLC 
grade and were filtered, de-gassed prior to use 
and applied to the column at the flow rate of 1 
ml/min. In IMAC, 15 mL chelating Sepharose 
Fast Flow gel (GE Healthcare, USA) was packed 
into the column (1.5 × 12 cm, Econo-Pac®) with 
column adaptor (Bio-Rad, USA). It was washed 
by water for injection (WFI) till the inlet and outlet 
pH and conductivity were the same. The column 
was sanitized by washing 2 column volumes with 
0.5 M NaOH solution. It was then neutralized by 
0.03 % (V/V) phosphoric acid and washed again 
with WFI. The column was equilibrated with 
phosphate buffered saline (PBS; pH 6.6 and 14 ± 
2 µS conductivity). Thereafter, 6 mM CuSO4 
solution was applied to the column till the 
absorption at 280 nm was above 0.2. Again the 
column was washed with washing buffer (7.5 g/L 
glycine, 7.8 g/L NaCl pH 2.2 and conductivity of 
33 ± 4 µS) till the absorption at 280 nm was 
below 0.2.  
 
After equilibration of the column, the refolded 
protein at each pH was loaded and washed first 
with 2 column volumes of PBS and then with 
sodium acetate solution (pH adjusted to 5 with 
glacial acetic acid). Finally, the protein was 
eluted with elution buffer (7.5 g/L glycine, 7.8 g/L 
NaCl pH 2.2 and conductivity of 33 ± 4 µS) and 
the eluted protein solution under the peak area 
was pooled for the next purification step. In the 
second step, Sephadex G-75 gel (15 mL of 
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swollen Sephadex) was packed in the column 
(1.5 × 12 cm, Econo-Pac®) using a column 
adaptor (Bio-Rad, USA). After packing, the 
column was sanitized with 0.5 M NaOH and 
washed with 2 column volumes of PBS (pH 6.6 
and 14 ± 2 µS conductivity). All packed columns 
qualities were controlled according to the 
company's instruction by loading 1 % V/V of 
acetone to the packed columns. Only columns 
with acceptable asymmetry factor range (0.8-1.5) 
was used.  
 
The equilibrated columns were loaded with 0.5 
ml of protein from the previous step and eluted 
with PBS (pH 6.6 and 14 ± 2 µS conductivity). 
The protein fractions were detected and collected 
at 280 nm based on standard rhIFN α-2b 
(Institute Pasteur, Iran) using a fraction collector 
unit equipped with ultraviolet detector (Bio-Rad, 
USA). The recovery of interferon from each 
purification step was calculated as: dividing the 
concentration of eluted interferon by 
concentration of applied interferon and multiplied 
by 100 to express it as percent recovery. The 
protein concentration of interferon α-2b was 
determined densitometrically by SDS-PAGE and 
GS-800™ densitometer (Bio-Rad, USA).  
 
Circular dichroism spectropolarimetry  
 
The percentage of α-helix and β-sheet in each 
refolded and purified recombinant human 
interferon α-2b at different pH was measured 
using a circular dichroism (CD) 
spectropolarimetry instrument at far UV regions 
(190 – 250) (JASCO 810 (Japan) based on 0.1 
cm path cell and scanning speed of 200 nm/min 
at 22 °C. The concentration of each refolded and 
purified recombinant human interferon α-2b at 
different pH was 0.1 µg/µL.  
 
In vitro bioassay 
 
The bioassay of rhIFN α-2b is based on the 
inhibitory activity of the interferon on the 
cytopathic effect of encephalomyocarditis virus 
on Hep2c cells. The potency is determined by 
protective effect of interferon against a cytopathic 
virus and comparing such with an appropriate 
standard interferon calibration in international 
unit. The standard rhIFN α-2b was obtained from 
National Institute of Biological Standards and 
Control, (NIBSC; Code 95/566). The bioassay 
was carried out according to British 
Pharmacopoeia 2012. The "relative potency" of 
the purified samples was determined and 
compared using ParLin version 5.0 software. The 
“comparative potency” was calculated by dividing 
the relative potency values of each pH by the 




Graphs were drawn by Excel 2007 and OriginPro 
version 7.0. Bioassay data were analyzed by 
PLA version 5 using one way ANOVA test. The 




Refolding efficacy at different pH 
 
A significant linear correlation between refolding 
efficacies and pH through pH increment up to pH 
8.0 was recorded and compared to the control 
pH 7.0 (p < 0.05). At pH 8.5 refolding efficacy 
was higher than at other pH values but the 
biological activity was decreased (Table 1). 
 
Purified refolded rhIFN α-2b and interferon 
recovery 
 
The electropherogram of the refolded and 
purified rhIFN α-2b reveals a 19 kDa band that 
showed 95 % purity of protein (Figure 1). 
Interferon recovery for each purification step was 
also calculated as listed in Table 2. 
 
 
Table 1: Comparison of refolding efficiency, relative and comparative potencies of rhIFN α-2b 
  
pH Refolding Efficiency (%) Relative Potency Comparative potency to pH 7.0 
7.0 42.28 ± 2.11 19353546.94 ± 1384515.09 1.00 
7.5 49.48 ± 2.04 24641854.72 ± 478347.18 1.27 
8.0 61.80 ± 2.85 28633902.24 ± 795729.06 1.48 
8.5 71.22 ± 2.59 21081305.00 ± 923234.28 1.09 
All experiments were performed in triplicate and data are represented as mean ± SD. For easy comparison, 
comparative potency was calculated by dividing relative potency of each pH values by relative potency value of 
pH 7.0 
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CD-spectropolarimetric data for purified 
rhIFN α-2b 
 
CD-spectropolarimetry revealed that with 
increasing pH of refolding medium, the percent of 
β-sheet present in the aforementioned protein 
was decreased whereas relative increment in α-
helix can be observed when compared with 
values at pH 7.0 (Table 3 and Figure 2). 
In vitro biological activity of refolded rhIFN α-
2b 
 
The in vitro biological activities of refolded rhIFN 
α-2b at pH 7.5 and 8.0 were significantly higher 





Figure 1: SDS-PAGE analysis of purified rhIFN α-2b on 12 % gel; Lane 1: pH 7.0, Lane 2: pH 7.5, Lane 3: rhIFN 
α-2b Standard (NIBSC; Code 95/566), Lane 4: Protein marker (Cat. No. 26610, Thermo Scientific, USA), Lane 5: 
pH 8.0 and lane 6: pH 8.5 
 
          Table 2: Interferon recovery in each purification step 
  
pH Interferon recovery in IMAC step (%)* Interferon recovery in SEC step (%)* 
7.0 84.5 ± 7.1 94.6 ± 6.7 
7.5 82.4 ± 9.4 90.2 ± 7.1 
8.0 85. ± 8.2 96.3 ± 5.6 
8.5 84.6 ± 9.3 89.8 ± 9.4 




Figure 2: CD-polarimetric spectra showing changes in secondary structure of refolded rhIFN α-2b at different 
pH values; (a) pH 8.5, (b) pH 7.0, (c) blank, (d) pH 8.0 and (e) pH 7.5 
 
Table 3: Secondary structure of refolded rhIFN α-2b determined by CD spectropolarimetry 
at different pH values 
 
pH Helix (%) Beta Sheet (%) Turn (%) Random Coil (%) 
7.0 23.7 46.0 0.0 30.3 
7.5 24.8 45.1 0.0 30.1 
8.0 27.3 43.1 0.0 29.6 
8.5 28.1 39.8 0.0 23.1 
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activity at pH 8.5 was dramatically decreased 
when compared to corresponding value at pH 8.0 
(Table 1).The highest potency i.e. 1.5-fold, 
caused by correct refolding of rhIFN α-2b, was 




The yield of correct folded protein and monomer 
formation depend strongly on the protein 
concentrations in initial step of refolding process 
[2,18]. The fact is that the effect of concentration 
variation was not minimized even by using the 
equal weight of pellets [4,5]. This may be due to 
different water contents of the harvested 
inclusion bodies when subjected to the refolding 
process. Therefore, the equal weight of IB leads 
to different protein concentration and refolding 
efficacy. In this study, concentration variation of 
rhIFN α-2b was eliminated by adjustment 
concentration before starting the refolding 
process. 
 
The main objective of all refolding methods in 
therapeutic protein production from inclusion 
bodies is to extract functional proteins with high 
yield and low cost [2]. Aggregation and 
aggregates are the main obstacles in preparation 
of functional proteins from inclusion bodies which 
contribute directly to the decrement in production 
or refolding yield of the target protein [2, 14]. This 
phenomenon can be avoided by using pH 
modulated refolding buffer. Based on previous 
studies, the Refolding efficacy (RE) was 
calculated as earlier suggested (Eq 1) [17]. 
 
RE = (C2V2/C1V1)100 ………………………. (1)  
  
where C1 is the concentration (mg/mL) of 
denatured and reduced protein inputted to the 
refolding process, V1 is the volume in (mL) of C1, 
C2 is the concentration of solubilized protein after 
the oxidized and refolding process and V2 is the 
final volume of refolding process (mL). 
 
On the other hand, C2 can be calculated as in Eq 
2. 
 
C2 = Cmf + Ccf + Cim ……………………… (2) 
 
where Cmf is the concentration of misfolded, Ccf is 
the concentration of correctly folded, Cim is the 
concentration of impurity. The units are in 
mg/mL.  
 
Therefore, refolding efficacy of correctly folded 
protein cannot be directly related to soluble 
protein [17]. The refolding efficacy is directly 
dependent on corrected, soluble-misfolded and 
soluble-impure proteins, it can be named “mixed 
refolding efficacy. If Cmf value was more 
considerable than Ccf value, the "mixed refolding 
efficacy" was quietly different from bioassay 
results and had no predictable relationship. So, 
the term of “mixed refolding efficacy” is fairly 
clearer than two-sided refolding efficacy term. In 
this study, unlike “mixed refolding efficacy” curve, 
the bioassay curve (was not shown) has 
hyperbolic shape with an optimum pH for correct 
refolding. In fact, increasing pH above 8.0 
dramatically decreases Ccf value. Thus, the 
previous data obtained from refolding efficacy 
revealed that solubilization cannot be a true 
approach to finding the optimum correct protein 
refolding conditions [16,17]. Data from this study 
showed that “mixed refolding efficacy”, correct 
folding of interferon, as determined by potency 
assay were increased simultaneously and was 
predictable till pH 8.0. At a pH higher than 8.0, 
the relationship between increment in 
solubilization and increase in biological activity 
disappeared. In other words, the increment in 
solubilization causes a reduction in biological 
activity and the highly difference appears 
between refolding efficacy and mixed refolding 
efficacy. Thus, data resulted from solubilization 
are not in accordance with biological activity and 
are misleading for estimating biological activity. 
Therefore, increasing pH results in increasing 
solubilization but cannot induce higher biological 
activity of rhIFN α-2b. 
 
In this study, purification method was applied to 
purify both folded and misfolded protein in order 
to directly investigate the effect of different pH on 
refolding process. By applying this procedure, 
the direct effect of pH on refolding of rhIFN α-2b 
was evaluated by in vitro assays. This study 
showed a complexity between solubilization and 
correct refolding of proteins. 
 
According to secondary structure analysis 
through CD spectropolarimeter, the changes in 
secondary structures of aforementioned protein 
(as compared to standard interferon α-2b 
obtained at pH 7.0) affect the biological activity of 
the protein. Structural changes from β-sheet to α-
helix, till pH 8.0 increased the protein potency. 
However, refolding of interferon α-2b at pH 8.5 
led to the spatial protein structure far away from 
its native structure. This can be related to the S-
S bound formation in the refolding process of IFN 
α-2b. 
 
Our results suggest that low refolding efficacy of 
IFN α-2b could be improved by increasing the 
proteins net charge using an optimized pH 
refolding medium (above isoelectric point of IFN 
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α-2b). Our data also show that the optimal pH for 
higher solubilization of IBs of interferon is pH 8.5 
but the optimal pH for highly functional protein 
recovery is pH 8.0. Since the amount of active 
protein recovery is more important than the 
amount of protein solubilization, this procedure 
can reduce the production cost and increase the 
amount of functional protein per batch of 
production. By changing only pH of the refolding 
buffer to the optimum point, the refolding efficacy 
and potency can be reached concurrently to the 




Employing a low-cost and simple method such 
as optimizing the pH of the refolding buffer 
results in higher refolding yield in downstream 
processing of rhIFN α-2b purification. In addition, 
our findings indicate that any method with high 
solubilization will not necessarily lead to active 
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